| Dr Michael C Gardner, MD | |
|
860 E Broad St Ste 1, Elyria, OH 44035-6542 | |
| (440) 323-8515 | |
| Not Available |
| Full Name | Dr Michael C Gardner |
|---|---|
| Gender | Male |
| Speciality | Anesthesiology |
| Experience | 12 Years |
| Location | 860 E Broad St Ste 1, Elyria, Ohio |
| Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1548528839 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207LP3000X | Anesthesiology - Pediatric Anesthesiology | 35.139521 (Ohio) | Primary |
| 207L00000X | Anesthesiology | 35.139521 (Ohio) | Secondary |
| Facility Name | Location | Facility Type |
|---|---|---|
| Mercy Regional Medical Center | Lorain, OH | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Elyria Anesthesia Incorporated | 7214902170 | 45 |
News Archive
Cell Therapeutics, Inc. today announced the initiation of an international cooperative group Phase 2 clinical trial of pacritinib in adult patients with relapsed acute myeloid leukemia (AML) with mutations of the FLT3 gene. Mutation of the FLT3 gene is found in approximately one-third of AML patients and is an independent risk factor for poor prognosis.
Although people may believe that their insurance worries are over once they qualify for Medicare, both doctors and patients are looking for a private option—especially with Medicare's looming bankruptcy, and ObamaCare's promise to cut half a trillion dollars from it to help fund universal coverage.
Oncotarget published "Molecular characterization of lung squamous cell carcinoma tumors reveals therapeutically relevant alterations" which reported that unlike lung adenocarcinoma patients, there is no FDA-approved targeted-therapy likely to benefit lung squamous cell carcinoma patients.
Mylan N.V. today announced that its abbreviated new drug application (ANDA) for fluticasone propionate 100, 250, 500 mcg and salmeterol 50 mcg inhalation powder has been accepted for filing by the U.S. Food and Drug Administration.
La Jolla Institute for Allergy & Immunology researchers studying an enzyme believed to play a role in allergy onset, instead have discovered its previously unknown role as a tumor suppressor that may be important in myeloproliferative diseases and some types of lymphoma and leukemia. Myeloproliferative diseases are a group of disorders characterized by an overproduction of blood cells by the bone marrow and include chronic myeloid leukemia. Lymphoma and leukemia are cancers of the blood.
› Verified 4 days ago
| Entity Name | Elyria Anesthesia Incorporated |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1710922463 PECOS PAC ID: 7214902170 Enrollment ID: O20040901001554 |
News Archive
Cell Therapeutics, Inc. today announced the initiation of an international cooperative group Phase 2 clinical trial of pacritinib in adult patients with relapsed acute myeloid leukemia (AML) with mutations of the FLT3 gene. Mutation of the FLT3 gene is found in approximately one-third of AML patients and is an independent risk factor for poor prognosis.
Although people may believe that their insurance worries are over once they qualify for Medicare, both doctors and patients are looking for a private option—especially with Medicare's looming bankruptcy, and ObamaCare's promise to cut half a trillion dollars from it to help fund universal coverage.
Oncotarget published "Molecular characterization of lung squamous cell carcinoma tumors reveals therapeutically relevant alterations" which reported that unlike lung adenocarcinoma patients, there is no FDA-approved targeted-therapy likely to benefit lung squamous cell carcinoma patients.
Mylan N.V. today announced that its abbreviated new drug application (ANDA) for fluticasone propionate 100, 250, 500 mcg and salmeterol 50 mcg inhalation powder has been accepted for filing by the U.S. Food and Drug Administration.
La Jolla Institute for Allergy & Immunology researchers studying an enzyme believed to play a role in allergy onset, instead have discovered its previously unknown role as a tumor suppressor that may be important in myeloproliferative diseases and some types of lymphoma and leukemia. Myeloproliferative diseases are a group of disorders characterized by an overproduction of blood cells by the bone marrow and include chronic myeloid leukemia. Lymphoma and leukemia are cancers of the blood.
› Verified 4 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Dr Michael C Gardner, MD 860 E Broad St Ste 1, Elyria, OH 44035-6542 Ph: (440) 323-8515 | Dr Michael C Gardner, MD 860 E Broad St Ste 1, Elyria, OH 44035-6542 Ph: (440) 323-8515 |
News Archive
Cell Therapeutics, Inc. today announced the initiation of an international cooperative group Phase 2 clinical trial of pacritinib in adult patients with relapsed acute myeloid leukemia (AML) with mutations of the FLT3 gene. Mutation of the FLT3 gene is found in approximately one-third of AML patients and is an independent risk factor for poor prognosis.
Although people may believe that their insurance worries are over once they qualify for Medicare, both doctors and patients are looking for a private option—especially with Medicare's looming bankruptcy, and ObamaCare's promise to cut half a trillion dollars from it to help fund universal coverage.
Oncotarget published "Molecular characterization of lung squamous cell carcinoma tumors reveals therapeutically relevant alterations" which reported that unlike lung adenocarcinoma patients, there is no FDA-approved targeted-therapy likely to benefit lung squamous cell carcinoma patients.
Mylan N.V. today announced that its abbreviated new drug application (ANDA) for fluticasone propionate 100, 250, 500 mcg and salmeterol 50 mcg inhalation powder has been accepted for filing by the U.S. Food and Drug Administration.
La Jolla Institute for Allergy & Immunology researchers studying an enzyme believed to play a role in allergy onset, instead have discovered its previously unknown role as a tumor suppressor that may be important in myeloproliferative diseases and some types of lymphoma and leukemia. Myeloproliferative diseases are a group of disorders characterized by an overproduction of blood cells by the bone marrow and include chronic myeloid leukemia. Lymphoma and leukemia are cancers of the blood.
› Verified 4 days ago
Dr. Kalva S. Reddy, M.D. Anesthesiology Medicare: Medicare Enrolled Practice Location: 630 E River St, Elyria, OH 44035 Phone: 440-329-7500 | |
Dr. Matthew Robert Meinert, M.D. Anesthesiology Medicare: Accepting Medicare Assignments Practice Location: 630 E River St, Elyria, OH 44035 Phone: 440-323-8515 | |
Dr. Emad Atalla, M.D. Anesthesiology Medicare: May Accept Medicare Assignments Practice Location: 630 E River St, Elyria, OH 44035 Phone: 440-329-7500 Fax: 440-323-7900 | |
Ashley Marie Logan, APRN CNP CCRN Anesthesiology Medicare: Medicare Enrolled Practice Location: 630 E River St, Elyria, OH 44035 Phone: 440-329-7500 | |
Maureen C Keshock, M.D. Anesthesiology Medicare: Accepting Medicare Assignments Practice Location: 630 E River St, Elyria, OH 44035 Phone: 440-329-7500 | |
Dennis Cieply, MD Anesthesiology Medicare: Accepting Medicare Assignments Practice Location: 630 E River St, Elyria, OH 44035 Phone: 440-329-7500 |